Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 10—October 2005


Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1

Jon P. Furuno*Comments to Author , Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
Author affiliations: *University of Maryland School of Medicine, Baltimore, Maryland, USA; †Veterans' Affairs Maryland Health Care System, Baltimore, Maryland, USA; ‡University of Maryland Medical Center, Baltimore, Maryland, USA

Main Article

Table 2

Components of final logistic regression models*

Characteristic MRSA/VRE co-colonization, OR (95% CI) VRE colonization, OR (95% CI) MRSA colonization, OR (95% CI)
Age 1.03 (1.01–1.05)
Male sex 1.93 (1.14–3.3)
Admission to MICU 4.38 (2.46–7.81) 1.84 (1.38–2.46)
Antimicrobial drugs during prior admission (<1 y) 3.06 (1.85–5.07) 3.38 (2.54–4.51) 1.66 (1.20–2.30)
Diabetes mellitus 1.39 (1.00–1.83) 1.83 (1.30–2.58)
Liver disease 1.64 (1.04–2.58)
Renal disease 2.28 (1.26–4.1)
Vancomycin 1.54 (1.03–2.31)
Piperacillin-tazobactam 1.77 (1.27–2.47)
Imipenem 2.47 (1.40–4.36)
Fluoroquinolones 2.01 (1.37–2.96)
HIV/AIDS 2.74 (1.46–5.14)

*Only variables significantly associated with the outcome are included in the final models. MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; OR, odds ratio; CI, confidence interval; MICU, medical intensive care unit.

Main Article

1These data were presented in part at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, September 2004.

2Current affiliation: Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.